Merck: new FDA approval for Keytruda
This approval is based on the results of a ph. III trial, which demonstrated a significant reduction in the risk of disease progression or death.
This trial is the first to statistically evaluate anti-PD-1 immunotherapy combined with chemotherapy in patients with pMMR and dMMR tumors.
This approval is important, as endometrial cancer is on the rise and is expected to surpass ovarian cancer deaths by 2024, the company points out.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction